HNRNPC Promotes Proliferation, Metastasis and Predicts Prognosis in Prostate Cancer

Wang, Shiyu; Xu, Guoxiong; Zhang, Cong; Han, Dunsheng; Chen, Gang

doi:10.2147/cmar.s330713

Cited by 23 publications

(20 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Statistics demonstrated that the morbidity rates of prostate cancer (PCa) have shown a remarkable increase worldwide, which seriously threatens public health and survival [ 1 , 2 ]. Surgery and radiation are the standard primary treatment against early patients with localized prostate malignancies, followed by androgen deprivation therapy (ADT), like surgical or chemical castration if this disease recurs.…”

Section: Introductionmentioning

confidence: 99%

The Roles of Tumor-Associated Macrophages in Prostate Cancer

Han

Deng

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

The morbidity of prostate cancer (PCa) is rising year by year, and it has become the primary cause of tumor-related mortality in males. It is widely accepted that macrophages account for 50% of the tumor mass in solid tumors and have emerged as a crucial participator in multiple stages of PCa, with the huge potential for further treatment. Oftentimes, tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) behave like M2-like phenotypes that modulate malignant hallmarks of tumor lesions, ranging from tumorigenesis to metastasis. Several clinical studies indicated that mean TAM density was higher in human PCa cores versus benign prostatic hyperplasia (BPH), and increased biopsy TAM density potentially predicts worse clinicopathological characteristics as well. Therefore, TAM represents a promising target for therapeutic intervention either alone or in combination with other strategies to halt the “vicious cycle,” thus improving oncological outcomes. Herein, we mainly focus on the fundamental aspects of TAMs in prostate adenocarcinoma, while reviewing the mechanisms responsible for macrophage recruitment and polarization, which has clinical translational implications for the exploitation of potentially effective therapies against TAMs.

show abstract

Section: Introductionmentioning

confidence: 99%

The Roles of Tumor-Associated Macrophages in Prostate Cancer

Han

Deng

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…Some studies found an association between HNRNPC and tumor progression, 46 , 47 , 48 as well as immune cell infiltration. 49 However, which immune cells can be regulated by HNRNPC , thus remodeling the TME is still unclear.…”

Section: Discussionmentioning

confidence: 99%

HNRNPC suppresses tumor immune microenvironment by activating Treg cells promoting the progression of prostate cancer

Cheng

Wei

et al. 2023

Cancer Science

View full text Add to dashboard Cite

Immune microenvironment could affect the biological progress in prostate cancer (PCa) through N6 methyl adenosine (m6A) methylation. The purpose of this study was to investigate the crosstalk between m6A methylation and immune microenvironment and explore potential biomarkers to improve the immunotherapeutic response. Firstly, according to 11 differentially expressed m6A genes between normal and tumor samples, PCa patients were divided into immune microenvironment subtype 1 (IMS1) and IMS2 based on m6A gene profiles extracted from The Cancer Genome Atlas (TCGA) database. IMS2 showed an immune “cold” phenotype with worse prognoses, and HNRNPC was identified as the biomarker of IMS2 by the protein‐protein interaction network. Furthermore, through bioinformatics analyses and in vitro experiments, we found that HNRNPC ‐high patients showed a suppressive immune‐infiltrating tumor microenvironment with a higher infiltration of regulatory T (Treg) cells. Finally, we cocultured transfected PCa cells with peripheral blood mononuclear cells (PBMC) and verified that HNRNPC inhibits tumor immunity by elevating the activation of Treg cells and suppression of effector CD8 T cell. In conclusion, we identified a “cold” immune phenotype in PCa, and HNRNPC regulating the activation of Treg cells. Activation of the immune microenvironment through targeting HNRNPC may be a potential therapeutic option for advanced PCa.

show abstract

“…Similar findings were also observed in other studies. Wang et al found that the expression of HNRNPC was significantly increased in prostate cancer tissues and positively correlated with the T stage, N stage, Gleason score, and PSA level [ 52 ]. Guo and colleagues also showed that HNRNPC was highly expressed in lung adenocarcinoma (LUAD) tissues and significantly related to smoking history, lymph node metastasis, and poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

Essential m6A Methylation Regulator HNRNPC Serves as a Targetable Biomarker for Papillary Renal Cell Carcinoma

Wei

Miao

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

m6A RNA modification is a common abundant posttranscriptional modification of mRNAs occurring in cancer growth and progression. Accumulated evidence has proved that HNRNPC, which acts as a m6A reader, plays an essential role in the promotion of cancer occurrence and development; nevertheless, the role of HNRNPC in papillary renal cell carcinoma remained to be discovered. In this study, we comprehensively identified HNRNPC as a hub gene involved in m6A modification in pRCC. Then, the expression level, survival outcomes, PPI network, function enrichment, immune cell infiltration, and single-cell analysis were performed. Finally, we found that HNRNPC significantly promoted renal cell carcinoma proliferation and migration in vitro. In conclusion, our work proved that HNRNPC may act as a momentous m6A regulator, as well as a potential targetable biomarker for pRCC.

show abstract

HNRNPC Promotes Proliferation, Metastasis and Predicts Prognosis in Prostate Cancer

Cited by 23 publications

References 59 publications

The Roles of Tumor-Associated Macrophages in Prostate Cancer

The Roles of Tumor-Associated Macrophages in Prostate Cancer

HNRNPC suppresses tumor immune microenvironment by activating Treg cells promoting the progression of prostate cancer

Essential m6A Methylation Regulator HNRNPC Serves as a Targetable Biomarker for Papillary Renal Cell Carcinoma

Contact Info

Product

Resources

About